Background <p>Antigen escape is one of the leading causes of relapse following chimeric antigen receptor (CAR)-T therapy, particularly in multiple myeloma. A critical gap persists in understanding the tumor-intrinsic pathways that trigger antigen loss, insight essential for devising strategies to resensitize tumors to immune attack. We identify a previously uncharacterized post-translational mechanism centered on the metabolic enzyme ribonucleotide reductase subunit…
Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy
Journal for ImmunoTherapy of Cancer | | Wang, Z., Wang, G., Liu, Y., Zhao, Y., Guo, S., Yang, Y., Zhang, Q., Hu, C., Chang, S., Wu, X., An, D., Hu, H., Cai, H., Zhang, L., Shi, J.
Topics: blood-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer